Literature DB >> 15623598

Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers.

Stephanie Curran1, Sinclair R Dundas, Jenny Buxton, Matthew F Leeman, Robin Ramsay, Graeme I Murray.   

Abstract

PURPOSE: The matrix metalloproteinases (MMPs) are a family of proteolytic enzymes involved in tumor invasion; several individual members of which have been implicated in tumor prognosis. These enzymes and their physiologic inhibitors, the tissue inhibitors of matrix metalloproteinases (TIMPs), act in a coordinated manner to form an integrated system. Therefore, to understand their role in tumor invasion, it is necessary to evaluate them collectively. EXPERIMENTAL
DESIGN: In this study all of the major members of the matrix metalloproteinase (MMP-1, MMP-2, MMP-3, MMP-7, MMP-9, MMP-13, MT1-MMP and MT2-MMP)/tissue inhibitor of matrix metalloproteinase (TIMP-1, TIMP-2, and TIMP-3) system have been investigated by immunohistochemistry in a series (n = 90) of stage III (Dukes' C) colorectal cancers. An immunohistochemical score based on the intensity of immunoreactivity and proportion of immunoreactive cells was established for each MMP and TIMP.
RESULTS: The MMP/TIMP profile defined by hierarchical cluster analysis of the immunohistochemical score identifies a distinct group of colorectal cancers with poor prognosis (log-rank test, 12.22, P = 0.0005). The median survival time of patients in this survival group was 18 months compared with a median survival of 49 months in the "good" survival group. Multivariate analysis showed that this profile was independently the most significant prognostic factor (P = 0.001).
CONCLUSIONS: This study has identified that the MMP/TIMP profile is an independent indicator of poor prognosis in colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15623598     DOI: 10.1158/1078-0432.CCR-04-0424

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  48 in total

1.  Alterations of glutathione S-transferase and matrix metalloproteinase-9 expressions are early events in esophageal carcinogenesis.

Authors:  Laszlo Herszenyi; Istvan Hritz; Istvan Pregun; Ferenc Sipos; Mark Juhasz; Bela Molnar; Zsolt Tulassay
Journal:  World J Gastroenterol       Date:  2007-02-07       Impact factor: 5.742

2.  Toll-Like Receptor 4 and Matrix Metalloproteases 11 and 13 as Predictors of Tumor Recurrence and Survival in Stage II Colorectal Cancer.

Authors:  Noemi Eiro; Juan Francisco Carrión; Sandra Cid; Alejandro Andicoechea; José Luis García-Muñiz; Luis O González; Francisco J Vizoso
Journal:  Pathol Oncol Res       Date:  2019-02-01       Impact factor: 3.201

3.  Overexpression of SMYD3 and matrix metalloproteinase-9 are associated with poor prognosis of patients with gastric cancer.

Authors:  Yong Liu; Honggen Liu; Xuegang Luo; Jingyu Deng; Yuan Pan; Han Liang
Journal:  Tumour Biol       Date:  2015-01-28

4.  Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions.

Authors:  Felipe De Sousa E Melo; Xin Wang; Marnix Jansen; Evelyn Fessler; Anne Trinh; Laura P M H de Rooij; Joan H de Jong; Onno J de Boer; Ronald van Leersum; Maarten F Bijlsma; Hans Rodermond; Maartje van der Heijden; Carel J M van Noesel; Jurriaan B Tuynman; Evelien Dekker; Florian Markowetz; Jan Paul Medema; Louis Vermeulen
Journal:  Nat Med       Date:  2013-04-14       Impact factor: 53.440

5.  Reactive oxygen species and tumor metastasis.

Authors:  Doo Jae Lee; Sang Won Kang
Journal:  Mol Cells       Date:  2013-02-21       Impact factor: 5.034

6.  Matrix metalloproteinase-9 expression in the normal mucosa-adenoma-dysplasia-adenocarcinoma sequence of the colon.

Authors:  László Herszényi; Ferenc Sipos; Orsolya Galamb; Norbert Solymosi; István Hritz; Pál Miheller; Lajos Berczi; Béla Molnár; Zsolt Tulassay
Journal:  Pathol Oncol Res       Date:  2008-03-18       Impact factor: 3.201

7.  Expression pattern of matrix metalloproteinases in human gynecological cancer cell lines.

Authors:  Andrea Schröpfer; Ulrike Kammerer; Michaela Kapp; Johannes Dietl; Sonja Feix; Jelena Anacker
Journal:  BMC Cancer       Date:  2010-10-13       Impact factor: 4.430

8.  RABEX-5 overexpression in gastric cancer is correlated with elevated MMP-9 level.

Authors:  Lili Kang; Xuwen Hao; Yanping Tang; Xiaodong Wei; Yanxia Gong
Journal:  Am J Transl Res       Date:  2016-05-15       Impact factor: 4.060

9.  Matrix metalloproteinase-14 is a negative prognostic marker for patients with gastric cancer.

Authors:  Liang He; Dake Chu; Xia Li; Jianyong Zheng; Shanhong Liu; Jipeng Li; Qingchuan Zhao; Gang Ji
Journal:  Dig Dis Sci       Date:  2013-01-13       Impact factor: 3.199

10.  Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: New findings and review of the literature.

Authors:  Andrea Köhrmann; Ulrike Kammerer; Michaela Kapp; Johannes Dietl; Jelena Anacker
Journal:  BMC Cancer       Date:  2009-06-16       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.